Johnson & Johnson said this week it has entered a deal to acquire hepatitis B virus (HBV) drug developer Novira Therapeutics Inc. by the end of the year. Read More »

EMD Millipore, Merck's life-sciences unit, has expanded its EMPROVE portfolio of pharmaceutical raw materials. The expanded portfolio of pharmaceutical raw materials assists drug-product manufacturers' risk assessment workflows and supplier qualifications. Read More »

Zafgen, Inc. announced Wednesday the completed enrollment of ZAF-203, a Phase 2b clinical trial of beloranib in the treatment of patients with both severe obesity and type 2 diabetes. Read More »

Tetraphase Pharmaceuticals, Inc. announced Tuesday that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections failed to meet its primary endpoint of statistical non-inferiority compared to levofloxacin. Read More »

Corbus Pharmaceuticals Holdings Inc. on Monday announced that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug, Resunab, designed for the treatment of diffuse cutaneous systemic sclerosis. Read More »

Sarepta Therapeutics Inc., a developer of RNA-targeted therapeutics, on Tuesday announced that the U.S. Food and Drug Administration (FDA) has filed the New Drug Application for eteplirsen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping. Read More »

TRICAST, a pharmacy data analytics company, said on Monday that it has joined with Brook Venture Partners and Blue Heron Capital in a growth-equity financing partnership."This is an exciting next step in the evolution of TRICAST," TRICAST CEO Greg Rucinski said. Read More »

Acton Pharmacy said late last week that it is partnering with MitoAction to support people with mitochondrial disease, a broad spectrum of disorders that affect an estimated 80,000 Americans. Acton Pharmacy will help expand outreach and support to mitochondrial disease patients by sponsoring MitoAction New England, a social and educational support group for patients and families in the area. Read More »

Catamaran Corp. and Health New England Inc. (HNE) recently announced one-year results from Catamaran’s Hospital Transition Program, revealing that the program has reduced HNE’s hospital readmission rates and increased medication adherence. Read More »

U.S. Oncology Research yesterday announced a new collaboration with Cure Forward, a patient activation company, to make personalized medicine more accessible in the community setting, reinforcing the teamwork between physicians and patients. Read More »

Former Prime Therapeutics CEO named non-executive chairman. Read More »

Software meant to assist health care organizations meet new Drug Supply Chain Security Act requirements. Read More »

CutisPharma, a specialty pharmaceutical company, yesterday named President Neal Muni as the company’s new CEO. Read More »

In 2014 the North American pharmacy information system market carried a value of more than $1.3 billion and its value is expected to increase to more than $2 billion by 2019, MicroMarket Monitor report said Monday. Pharmacy Information Systems (PIS) is an application used by medication dispensaries to increase patient safety by helping decrease the amount of errors in the dispensing process. It also provides information about dosage times and limits for specific patients based on their age, we Read More »

Johnson and Johnson said on Saturday that Janssen Research and Development, LLC, a Johnson and Johnson subsidiary, is partnering with the medical-ethics division at the New York University School of Medicine to evaluate compassionate use of investigational medicines. Read More »

The Generic Pharmaceutical Association on Thursday announced that launch of the Biosimilars Council, a division of GPhA. Read More »

A working paper recently published as part of a National Bureau of Economic Research series examines whether the introduction of the Medicare Prescription Drug Benefit Program in 2006 may have contributed to an increase in prescription drug abuse. Read More »

Sarepta Therapeutics, Inc., an RNA-targeted therapeutics developer, on Tuesday announced that Edward Kaye has been appointed as interim CEO. Read More »

Wellframe said on Monday that it is partnering with Shields Pharmacy Services to extend the reach of Shields Medication Management Liaisons to better promote patient medication adherence, engagement and relationship management. Read More »